Skip to main content
Premium Trial:

Request an Annual Quote

Paul Billings, Robert Friel, Gregory Summe, Richard Wender, Kerry Frey, Eric Henderson

Paul Billings has been appointed chairman of Signature Genomic Laboratories’ board of directors, the firm said this week.
Billings previously was senior vice president for corporate development and senior geneticist at Laboratory Corporation of America. He has also been executive vice president and chief scientific and medical officer at GeneSage.
Billings received his MD and his PhD in immunology from Harvard University in 1979 and completed his clinical training in internal medicine and medical genetics at the University of Washington in Seattle in 1983.

PerkinElmer last week said that company President and Chief Operating Officer Robert Friel will replace current CEO Gregory Summe on Feb. 1. In accordance with the company’s planned strategy for succession of responsibility, Summe will continue to hold his post as executive chairman of the board through April 2009.
Friel, who started at PerkinElmer in 1999 as chief financial officer and was promoted to president and COO in 2007, will retain his post as president.

Epigenomics has named Richard Wender to the company’s medical advisory board for colorectal cancer screening.
Wender is alumni professor and chair of the Department of Family and Community Medicine at Thomas Jefferson University in Philadelphia.

BioForce Nanosciences has shuffled its management, making President and Chief Operating Officer Kerry Frey the new CEO, while retaining the title of president, and moving current CEO Eric Henderson into the post of executive vice president and chief scientific officer, a newly created position.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more